Table 1.
Pathological information of cohorts included in this study. UTokyo, University of Tokyo; TCGA, The cancer genome atlas; EBV, Epstein-Barr virus; MSI, Microsatellite instability; dMMR, mismatch repair deficiency; CIN, chromosomal instable; GS, genomically stable; NA, not available.
| Parameters | UTokyo (training) | UTokyo (test) | TCGA |
|---|---|---|---|
| Total number of samples | 326 | 82 | 244 |
| Molecular classification | |||
| EBV | 87 (26.7%) | 21 (25.6%) | 23 (9.4%) |
| MSI/dMMR | 46 (14.1%) | 12 (14.6%) | 44 (18.0%) |
| Others | 193 (59.2%) | 49 (59.8%) | 177 (72.5%) |
| CIN | 127 (52.0%) | ||
| GS | 50 (20.5%) | ||
| Lauren classification for non-EBV and non-MSI/dMMR tumors | |||
| Intestinal | 100 (51.8%) | 26 (53.1%) | 114 (64.4%) |
| Diffuse | 93 (48.2%) | 23 (46.9%) | 51 (28.8%) |
| Mixed | 11 (6.2%) | ||
| NA | 1 (0.6%) | ||
| pT stage | |||
| pT1 | 158 (48.5%) | 40 (48.8%) | 9 (3.7%) |
| pT2 | 39 (12.0%) | 9 (11.0%) | 36 (14.8%) |
| pT3 | 66 (20.2%) | 17 (20.7%) | 142 (58.2%) |
| pT4 | 63 (19.3%) | 16 (19.5%) | 57 (23.4%) |